HALO Diagnostics Partners with Ikonopedia to Offer Comprehensive Women's Health Genetic Testing to Improve Early Detection of Breast Cancer

HALO Diagnostics Partners with Ikonopedia to Offer Comprehensive Women’s Health Genetic Testing to Improve Early Detection of Breast Cancer

Integrated approach supposed to triple early detection in high-risk women; Five-year survival rate increases to 99% with early diagnosis

LOS GATOS, CA. and RICHARDSON, TX, November 28, 2022 /PRNewswire/ — HALO Diagnostics, the leader in early disease detection using precision diagnostics, and Ikonopedia, a next-generation breast imaging tracking and reporting solution, today announced a genetic testing partnership to improve breast cancer detection and patient outcomes.

Genetic testing is the most effective way to determine if a patient has specific disease-causing mutations linked to a higher risk of developing cancer, but only one in five women likely to be tested for hereditary cancer are offered this option.1 Without integrated genetic testing and additional breast MRIs, traditional imaging centers miss two out of three cancers in high-risk women.2

HALO and Ikonopedia use genetic testing to find cancers early and increase adherence to critical follow-up imaging. Under this new partnership, Ikonopedia’s state-of-the-art mammography software for follow-up tracking and one-click radiology reporting will be seamlessly integrated with HALO’s proprietary genetic laboratory and precision diagnostic software services. This integrated approach is expected to result in a 40% increase in compliance for follow-up imaging,3 facilitating early detection and less invasive treatment.

  • Almost all patients (97%) with positive genetic test results comply with additional screening recommendations.3
  • The cancer detection rate is increased threefold with additional breast MRI screening in high-risk women.4
  • More than 99% of patients survive more than five years with an early stage breast cancer diagnosis.5

The joint offering aims to maximize patient risk identification using Tyrer-Cuzick 8, HALO’s Inherited Gene Panel and HALO’s Polygenic Risk Score. The partnership offers radiology centers:

  • HALO’s proprietary genetic lab and precision diagnostic software services with integrated genetic counseling, and a dedicated lab liaison who will work on-site at the radiology center.
  • Seamless admissions integration, automatic eligibility checks, automatic lab ordering, and lab processing.
  • Comprehensive precision diagnostic report including recommended follow-up imaging for patients identified as being at high risk for breast cancer.

“We are proud to partner with Ikonopedia and their robust breast imaging risk assessment and reporting tools,” said Brian Ax, Founder and Product Manager of HALO. “Our combined solution will save lives by improving early detection through rapid, accurate diagnosis and personalized care.”

As part of this collaboration, Ikonopedia’s integrated risk assessment tool will identify patients eligible for hereditary testing. When medically indicated, physicians will place an order for HALO’s proprietary Women’s Health Precision Diagnostics Suite, which combines advanced imaging, a risk calculator and genetic test results to identify patients who may benefit. additional screening and treatment for breast cancer.

“HALO and Ikonopedia’s goals for early detection and personalized treatment are incredibly well aligned. We are thrilled to partner with a forward-thinking precision diagnostics company to enable broader access to genetic testing and better follow-up,” said Emilie CraneCEO and President of Econopedia.

About HALO

HALO Diagnostics is the leader in early disease detection using precision diagnostics. The company’s ambulatory precision diagnostic centers are reshaping the healthcare ecosystem by integrating advanced imaging, digital pathology, molecular genomics and predictive analytics under one roof, in a cost-effective ambulatory setting. HALO makes early disease detection and diagnosis faster and more convenient for patients and physicians. With dedicated care pathways for prostate cancer, breast cancer, heart disease, lung disease and dementia, HALO increases early disease detection and saves lives. HALO currently serves one million patients, a number expected to triple by 2024. For more information, visit www.halodx.com.

About Ikonopedia

Ikonopedia was founded by three expert radiologists in breast imaging: László Tabár, MD is the author of 6 books in 10 languages ​​on mammography and a world-renowned educator; A. Thomas Stavros, MD is the author of one of the most popular reference books in the field of breast ultrasound; and Michael J. Vendrell, MD is a breast MRI and CAD design expert with extensive experience in breast imaging software. For more information, visit www.ikonopedia.com.

HALO Media Contact:
Capwell Communications
[email protected]

Ikonopedia media contact:
[email protected]

1. Childers CP, et al. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol. 2017 1st December;35(34):3800-3806. PMC5707208.
2. Riedl CC, et al. Tri-modality screening trial for familial breast cancer highlights importance of magnetic resonance imaging and questions role of mammography and ultrasound regardless of the patient’s mutation status, age, and breast density. Journal of Clinical Oncology. 2015;33(10):1128-35. PMC5526626.
3. Vysotskaia V, Kaseniit KE, Bucheit L, Ready K, Price K, Johansen Taber K. Clinical utility of hereditary cancer screening tests: impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C and RAD51D results on patient management and compliance with provider recommendations. Cancer. 2020;126(3):549–58. https://doi.org/10.1002/cncr.32572
4.BaeMS, Sun JS, Bernard-Davila B, Sutton EJ, Comstock CE, Morris EA. Survival outcomes of breast MRI screening in women at high risk for breast cancer. J Breast imaging. 2020 Feb;2(1):29-35. doi: 10.1093/jbi/wbz083. Epub 15 Jan 2020. PMID: 32055796; PMCID: PMC6999769. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999769/
5. Farhad IslamiMD, PhD, Elizabeth M Ward, PhD, Hyun-sungPhD, Kathleen A Cronin, PhD, Florence KL Tangka, PhD, Recinda L Sherman, PhD, Jingxuan ZhaoMPH, Robert N Anderson, PhD, S Jane Henley, MSPH, K Robin Yabroff, PhD, Ahmadine JamalDVM, PhD, Vicki B Benard, PhD, Annual Report to the Nation on the State of Cancer, Part 1: National Cancer Statistics, JNCI: Journal of the National Cancer Institute, Volume 113, Number 12, December 2021Pages 1648–1669, https://doi.org/10.1093/jnci/djab131


#HALO #Diagnostics #Partners #Ikonopedia #Offer #Comprehensive #Womens #Health #Genetic #Testing #Improve #Early #Detection #Breast #Cancer

Leave a Comment

Your email address will not be published. Required fields are marked *